Tuesday, September 10, 2019
Wize Pharma, Inc. a clinical-stage biopharmaceutical company focused on the treatment of ophthalmic disorders, today announced it has entered into an Exclusive License Agreement with U.S.-based Copernicus Therapeutics, Inc., pursuant to which, at the closing, it will be granted exclusive rights to license, develop and commercialize products based on a non-viral gene therapy technology developed by Copernicus for the treatment of Choroideremia (CHM).
"We are very pleased and excited to enter into this agreement with Copernicus. Their proprietary and innovative technology addresses what we believe to be the greatest challenges in gene therapy, including overcoming the potential immune system response to treatment, thereby allowing repeated treatments if necessary. As an ophthalmology focused company, Wize is eager to develop and commercialize this cutting-edge gene therapy to transform the treatment of eye related diseases," stated Mark Sieczkarek, Chairman of the Board of Directors of Wize.
Dr. Robert Moen, President and CEO of Copernicus, commented, "Copernicus's gene therapy approach uniquely offers efficacy for ocular therapeutics without toxicity. We believe our disruptive technology is a paradigm shift in the field of gene therapy because it is a non-viral option, as compared to the viral-based systems that have dominated the field to date. We are very excited to advance our ophthalmic indications into the clinic with Wize Pharma."